BI 105273

BI 105273 is an investigational drug developed by Boehringer Ingelheim. It is a small molecule designed as a selective antagonist of the chemokine receptor CCR2. The primary therapeutic rationale for BI 105273 is to inhibit the recruitment and activation of monocytes/macrophages mediated by CCL2-CCR2 signaling, which plays a key role in inflammatory and fibrotic diseases. The main indication under investigation for BI 105273 has been nonalcoholic steatohepatitis (NASH), where monocyte-driven inflammation contributes to disease progression. As of current knowledge, clinical development has not advanced beyond early-phase trials, and there are no approved indications.